THE US Food and Drug Administration has approved the expanded use of a test called the Vidas Brahms PCT Assay, to help health professionals determine whether antibiotic treatment should be started or stopped in patients with lower respiratory tract infections such as pneumonia, and stopped in patients with sepsis.
It is the first test to use procalcitonin (PCT) as a biomarker to help make antibiotic management decisions.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 17
